Sign In
Buy JNJ
$239.08
+7.79 (+3.37%)
At Close: Jun 23, 2026
Johnson & Johnson $JNJ Shares Bought by Avantax Advisory Services Inc.
04:34am, Sunday, 16'th Nov 2025
Avantax Advisory Services Inc. lifted its stake in shares of Johnson and Johnson (NYSE: JNJ) by 1.4% in the second quarter, according to the company in its most recent disclosure with the SEC. The ins
Major stock indexes were mixed Friday, with the Dow Jones Industrial Average declining for a second straight session but technology shares rebounding.
Biopharma companies have confidence in their ability to do deals: BMO's Evan Seigerman
03:19pm, Friday, 14'th Nov 2025
Evan Seigerman, BMO Capital Markets head of health care research, joins 'Power Lunch' to discuss what's behind the recent move in health care stocks, the state of play with GLP-1s and much more.
Bristol Myers, J&J halt heart drug trial after interim review
08:03am, Friday, 14'th Nov 2025
Bristol Myers Squibb and Johnson & Johnson said on Friday they would stop a late-stage trial of their experimental blood clot drug in heart attack patients, after an independent review found the study
Johnson & Johnson $JNJ Shares Sold by Arvest Bank Trust Division
04:12am, Friday, 14'th Nov 2025
Arvest Bank Trust Division reduced its holdings in Johnson and Johnson (NYSE: JNJ) by 4.5% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission
Why Is Johnson & Johnson (JNJ) Up 1.7% Since Last Earnings Report?
12:31pm, Thursday, 13'th Nov 2025
Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock?
2 Healthcare Stocks for Beginner Investors With a 40-Year Time Horizon
05:04am, Thursday, 13'th Nov 2025
These companies are leaders in their respective industries and are both very profitable. Intuitive Surgical has been the dominant presence in the surgical robotics market for decades.
2 Strong Healthcare Stock Picks for Dividend Investors
03:55am, Thursday, 13'th Nov 2025
These companies have exceptional dividend track records. AbbVie is moving on from its Humira patent losses, and its portfolio benefits from some exceptionally profitable products.
Want Decades of Passive Income? 2 Stocks to Buy Now and Hold Forever.
11:01am, Wednesday, 12'th Nov 2025
CVS Health is successfully navigating industrywide and company-specific headwinds while maintaining a solid dividend program. Johnson & Johnson's rock-solid balance sheet and ability to develop brand-
J&J's MedTech Unit Sales Improve: Will the Momentum Last?
07:56am, Wednesday, 12'th Nov 2025
J&J's MedTech sales rose 5.6% in Q3, fueled by cardiovascular strength and strategic portfolio shifts toward high-growth markets.
Johnson & Johnson (JNJ) Presents at UBS Global Healthcare Conference 2025 Transcript
01:41pm, Tuesday, 11'th Nov 2025
Johnson & Johnson ( JNJ ) UBS Global Healthcare Conference 2025 November 11, 2025 11:00 AM EST Company Participants Peter Menziuso Conference Call Participants Danielle Antalffy - UBS Investment Bank,
Johnson & Johnson (JNJ) Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference Transcript
12:51pm, Tuesday, 11'th Nov 2025
Johnson & Johnson ( JNJ ) Guggenheim Securities 2nd Annual Healthcare Innovation Conference November 11, 2025 10:30 AM EST Company Participants Sarah Brennan Mark Wildgust Conference Call Participants
Wall Street Analysts See Johnson & Johnson (JNJ) as a Buy: Should You Invest?
10:31am, Tuesday, 11'th Nov 2025
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employe
Johnson & Johnson: 2 Recent FDA Wins And Earnings Beat Warrant 'Buy' Rating
06:26am, Monday, 10'th Nov 2025
Johnson & Johnson remains a "buy" following strong Q3 2025 results, driven by robust sales growth and raised full-year 2025 revenue guidance. The company's acquisition of Intra-Cellular Therapies and
Got $1,000? Here Are the Smartest Dividend Stocks to Start With.
04:15am, Monday, 10'th Nov 2025
Dividend stocks perform well in market corrections. These stocks are in three defensive sectors.
